![]() |
||||||||||||||||||||||||||
![]() |
![]() |
![]() |
![]() |
|||||||||||||||||||||||
NEWS AND EVENTS: CERUS ISBT SYMPOSIUMCerus Symposium: ISBT 2007 (Madrid, Spain - June 26, 2007)
A Single Pathogen Inactivation System for Two Blood Components: INTERCEPT Blood System for Platelets and Plasma The symposium, “A Single Pathogen Inactivation System for Two Blood Components: INTERCEPT Blood System for Platelets and Plasma” was held as part of the XVIIth International ISBT Congress. The INTERCEPT Blood System has
now been in routine use for several years in Europe, and with our recent CE mark for plasma
The Presenters
Dr. AuBuchon attended the University of Michigan for undergraduate work in
cellular biology and then for medical school before entering the fi eld of pathology.
He completed an anatomic and clinical pathology residency at the University of
Wisconsin and was a Senior Staff Fellow in the Department of Transfusion Medicine
at the National Institutes of Health. Following his fellowship, Dr. AuBuchon served as Dr. AuBuchon came to Dartmouth-Hitchcock Medical Center as the Medical Director
of the Blood Bank and Transfusion Service in 1990. He has pursued several lines
of research, continuing his work on component storage system improvement and
extending his interest in practical improvements in blood safety through defining the Dr. AuBuchon has served as the Pathology Residency Program Director for fourteen years and as chair of the Department of Pathology for six years. He served as a member of the Advisory Committee on Blood Safety and Availability of the U.S. Department of Health and Human Services (1997-2000). He has served the American Association of Blood Banks as chair of the Scientific Section Coordinating Committee (1998-2002) and a district director (2003 – present) on the Board of Directors. He chairs the Transfusion Medicine Resource Committee of the College of American Pathologists. He chaired the Biomedical Excellence for Safer Transfusion Collaborative fom 2002 to 2006. He was elected a Fellow of the Royal College of Physicians of Edinburgh in 1999.
Dr. Henschler is Head of Department of
Production of Institute for Transfusion Medicine
and Immune Hematology, German Red Cross Dr. Henschler has extensive experience in experimental haematology, internal medicine and laboratory medicine. He was Head of stem cell laboratory at Freiburg
University Medical Center before joining the
German Red Cross in Frankfurt in 1999. Dr. Castro studied medicine at the La Laguna
University, Spain and obtained the degree of
Doctor of Medicine in 1981. She became Dr. Castro was a medical Resident at the
Haematology and Blood Bank Department;
Nuestra Señora de Aranzazu Hospital, San Dr. Castro became the Medical Director of the Spanish Red Cross Blood Center of Madrid (Centro de Transfusión de Cruz Roja Española), Spain in 1995 and has held the position of CEO since 1996. Dr. Castro has extensive experience in blood
banking and transfusion medicine and has
published extensively in the field of transfusion
Jean-Pierre Cazenave was born in L’Aigle,
France, on May 6th 1943. He moved to Canada where he lived for
8 years. He joined the research group of
Professor J.F. Mustard at Mac Master University, He has more recently devoted his research to
experimental models of platelet transfusion and
to clinical studies of pathogen inactivation of He is Professor of Hematology and Transfusion at University Louis Pasteur, Faculty of Medicine of Strasbourg, member of several international societies and author of 500 publications. He has been elected as corresponding member
(3rd Division, Biological Sciences) of the
Académie Nationale de Médecine. Paris,
|
||||||||||||||||||||||||||
©
Cerus Corporation. All Rights Reserved. | Legal
Info | Privacy Policy |
||||||||||||||||||||||||||
Use of the INTERCEPT Blood
System in the United States is limited by Federal law to investigational
use. If you are a resident of the U.S., please
click here.
The information on this site is not country-specific, and may contain
information that is outside the approved indications for the country
in which you are located.
The INTERCEPT Blood System has received approval for CE Marking for
use with platelets and plasma. |